Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacotherapy for the Prevention of Ventilator-associated Pneumonia.

American journal of respiratory and critical care medicine·2025

Same author

Evaluation of Glycemic Variability and Discharge Outcomes in Patients with Ischemic Stroke Following Thrombolysis.

The Neurohospitalist·2024

Same author

Perioperative Anticoagulation in Patients with Cancer.

Current oncology reports·2023

Same author

Ideal Foundational Requirements for Stroke Program Development and Growth: A Scientific Statement From the American Heart Association.

Stroke·2023

Same author

Perioperative Anticoagulation Management.

Critical care nursing quarterly·2022

Same author

SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.

Critical care nursing quarterly·2022

Search research articles

Related Experiment Video

Updated: Nov 29, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Changing Fields-Diabetes Medications Invading the Cardiovascular Space.

Lauren D Breite, Mackenzie Steck, Brandon Tate Cutshall

Current Problems in Cardiology

|November 21, 2020

Summary

For type 2 diabetes patients, glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors offer the greatest cardiovascular benefits. Avoid sulfonylureas in those with cardiovascular disease (CVD) risk.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Experiment Videos

Last Updated: Nov 29, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

Endocrinology
Cardiology
Pharmacology

Background:

Cardiovascular disease (CVD) is the primary cause of death in type 2 diabetes (T2D) patients.
Identifying antidiabetic agents that improve cardiovascular (CV) outcomes is crucial.
Evidence for pharmacologic CVD risk reduction in T2D is expanding.

Purpose of the Study:

To review the literature on the CV effects of antidiabetic medications.
To offer practical recommendations for using these agents in T2D patients with CVD.

Main Methods:

Literature review of studies on antidiabetic agents and their cardiovascular impact.
Analysis of clinical trial data and expert guidelines.

Main Results:

Glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors provide significant CV benefits when added to metformin.
Sulfonylureas should be avoided in patients at high CVD risk.
Pioglitazone may be a preferred thiazolidinedione option for CVD patients.

Conclusions:

The choice of antidiabetic agent should balance CV benefit, risk, and cost.
GLP-1 agonists and SGLT-2 inhibitors are recommended for most T2D patients to reduce CV risk.
Careful consideration of individual patient profiles is essential for optimal treatment selection.